


CERTIFICATE OF ANALYSIS

Compound	Melanotan II (MT-2)
Pack size	10 mg
Batch identifier	PR-MT2-2604-001
Manufacturing date	2026-04-10
Testing date	2026-04-18
Testing laboratory	Independent third-party Australian laboratory

1. HPLC PURITY (REVERSED-PHASE, UV 220 NM)

Method: Reversed-phase high-performance liquid chromatography on a C18 column. Mobile phase: gradient acetonitrile in water with 0.1% trifluoroacetic acid. Detection at 220 nm. Purity reported as percent area under main peak relative to total integrated area.



Result 99.4% (≥ 98% specification)

2. MASS SPECTROMETRY (IDENTITY)

Method	Electrospray ionisation mass spectrometry (ESI-MS)
Molecular formula	C ₅₀ H ₆₉ N ₁₅ O ₉
Theoretical mass	1024.18 Da
Observed mass	1024.20 Da
Result	Identity confirmed

3. ENDOTOXIN (LAL ASSAY)

Method	Limulus amoebocyte lysate (LAL) chromogenic assay
Result	0.25 EU/mg (low-endotoxin specification)

4. STORAGE AND HANDLING

Store lyophilised (unreconstituted) at 2–8 °C. Protect from light and moisture. Avoid repeated freeze–thaw cycles after reconstitution. Refer to the Pillar Research reconstitution and storage guide for full handling procedure.

REGULATORY STATUS

This compound is supplied for in vitro laboratory and educational research only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth). Not for human or animal consumption, therapeutic use, or diagnostic procedures. Research Use Only (RUO).

Released by
QA Officer, Pillar Research
Date: 2026-04-30

Document control
Document: COA-MELANOTAN-II-10MG
Version: 1.0

SAMPLE — NOT FOR DISPA